CLINICAL TRIALS PROFILE FOR TOBRAMYCIN SULFATE

All Clinical Trials for TOBRAMYCIN SULFATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01938417 ↗	Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute	Completed	University of Lausanne Hospitals		2006-10-01	This study aimed to assess the systemic absorption and disposition of tobramycin in patients treated with a tobramycin-laden bone graft substitute (Osteoset® T).
NCT03308253 ↗	Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection	Unknown status	McMaster University	Phase 4	2018-07-16	The CDC quotes a rate of wound infection of 2-5% for inpatient surgery. Patients undergoing a vascular operation, however, are generally at an increased risk of wound infection with rates often close to 5-10%. Groin incisions are an additional risk factor for surgical site infections, with rates of wound infection being quoted from 10-15%, and even as high as 30% in high risk patients. The use of implantable calcium sulfate beads mixed with antibiotics may help to lower the rate of infection in these high risk patients.
NCT04662632 ↗	Abbreviated Protocol for Two-Stage Exchange	Recruiting	Joint Purification Systems	Phase 2	2021-07-01	Study Type: A multi-site, parallel group, randomized trial. Study Objectives: The objective is to evaluate safety and determine preliminary efficacy of VT-X7. Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint of Overall Success at 90 days, consisting of a revision prosthesis implanted at Stage 2, patient survival, absence of reoperation and absence of PJI. Secondary objectives are to evaluate superiority at 365 days in a composite endpoint of Overall Success, and in separate secondary endpoints for quality of life (QoL) and patient survival. The exploratory objective is to compare Experimental and Control Arms in exploratory endpoints. Follow-up: Patients will be evaluated at 90-, 180-, and 365-day follow-up visits.
NCT04662632 ↗	Abbreviated Protocol for Two-Stage Exchange	Recruiting	Osteal Therapeutics, Inc.	Phase 2	2021-07-01	Study Type: A multi-site, parallel group, randomized trial. Study Objectives: The objective is to evaluate safety and determine preliminary efficacy of VT-X7. Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint of Overall Success at 90 days, consisting of a revision prosthesis implanted at Stage 2, patient survival, absence of reoperation and absence of PJI. Secondary objectives are to evaluate superiority at 365 days in a composite endpoint of Overall Success, and in separate secondary endpoints for quality of life (QoL) and patient survival. The exploratory objective is to compare Experimental and Control Arms in exploratory endpoints. Follow-up: Patients will be evaluated at 90-, 180-, and 365-day follow-up visits.
NCT05279586 ↗	Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients	Not yet recruiting	Madonna Magdy Fahmy	Early Phase 1	2022-03-01	The aim of this study is to compare the efficacy and safety of colistin versus lactulose for secondary prophylaxis of overt hepatic encephalopathy in patients with liver cirrhosis.
NCT05607030 ↗	A Second Trial of the Abbreviated Protocol Two-Stage Exchange	Not yet recruiting	Osteal Therapeutics, Inc.	Phase 2	2022-11-30	Apex-2 is a multi-site, parallel group, randomized trial. Patients will be randomly assigned in a 1:1 ratio to the Experimental Arm or the Control Arm. The objective of the study is to evaluate safety and determine efficacy of the VT-X7 system. Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint of Overall Success at 180 days, consisting of a revision prosthesis implanted at Stage 2, absence of PJI, absence of continued antiobiotic therapy for treatment or prophylaxis of PJI, absence of revision surgery and absence of mortality. Secondary objectives are to evaluate overall success at 365 days, overall safety of the VT-X7 procedure, quality of life (QoL), and patient survival. The exploratory objective is to compare Experimental and Control Arms in exploratory endpoints. Follow-up: Patients will be evaluated at 90-, 180-, and 365-day follow-up visits.

Clinical Trial Conditions for TOBRAMYCIN SULFATE

Condition Name

Condition Name for TOBRAMYCIN SULFATE
Intervention	Trials
Hepatic Encephalopathy	1
Orthopedic Operations	1
Prosthetic Joint Infection	1
Prosthetic-joint Infection	1

Condition MeSH

Condition MeSH for TOBRAMYCIN SULFATE
Intervention	Trials
Infections	3
Infection	2
Hepatic Encephalopathy	1
Brain Diseases	1

Clinical Trial Locations for TOBRAMYCIN SULFATE

Trials by Country

Trials by Country for TOBRAMYCIN SULFATE
Location	Trials
United States	12
Canada	1

Trials by US State

Trials by US State for TOBRAMYCIN SULFATE
Location	Trials
Utah	1
Pennsylvania	1
Oklahoma	1
Ohio	1
North Carolina	1

Clinical Trial Progress for TOBRAMYCIN SULFATE

Clinical Trial Phase

Clinical Trial Phase for TOBRAMYCIN SULFATE
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	2
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for TOBRAMYCIN SULFATE
Clinical Trial Phase	Trials
Not yet recruiting	2
Unknown status	1
Completed	1

Clinical Trial Sponsors for TOBRAMYCIN SULFATE

Sponsor Name

Sponsor Name for TOBRAMYCIN SULFATE
Sponsor	Trials
Osteal Therapeutics, Inc.	2
McMaster University	1
Joint Purification Systems	1

Sponsor Type

Sponsor Type for TOBRAMYCIN SULFATE
Sponsor	Trials
Industry	3
Other	3

Tobramycin Sulfate: Clinical Trials Update, Market Analysis, and Projection

Last updated: May 3, 2026

What is tobramycin sulfate in the commercial and clinical landscape?

Tobramycin sulfate is an aminoglycoside antibiotic used to treat serious bacterial infections, with the dominant modern use in inhaled form for chronic airway infection in cystic fibrosis (CF), most notably due to Pseudomonas aeruginosa. Commercially, the product is defined by formulation and delivery system rather than the active moiety alone: inhaled tobramycin products (nebulized) drive the core market, while other routes (including ophthalmic and topical) exist but track separate indication-specific market dynamics.

Key implication for market sizing and trial interpretation: clinical trial activity and commercial momentum cluster by route + indication (primarily inhaled CF-related Pseudomonas), and regulatory exposure differs by jurisdiction and product lineage.

What does the approved clinical profile look like (and why it matters for trials)?

Across global labels, the inhaled tobramycin standard-of-care structure has historically used alternating dosing cycles (on/off) in CF, and regulators and payers recognize a long-established efficacy and safety rubric for inhaled aminoglycosides. This affects trial design economics: newer trials in the same patient population often aim at:

• Demonstrating non-inferiority or equivalence versus an existing inhaled comparator
• Improving device convenience or dose delivery consistency
• Addressing pharmacokinetic/pharmacodynamic characteristics in the target population

What is the current clinical trials update for tobramycin sulfate (what to watch)?

No complete, verifiable clinical trials dataset can be produced in this response because the necessary live trial registry extraction (e.g., from ClinicalTrials.gov or EU CTR with filters by “tobramycin sulfate” and by route/formulation) is not provided in the prompt, and the response is constrained to hard data only.

What is the market analysis for tobramycin sulfate?

Tobramycin’s market is best analyzed by:

• Product format: nebulized inhalation products for CF
• Indication: CF chronic P. aeruginosa infection, plus other uses in distinct categories
• Geography: where CF treated populations and reimbursement frameworks support inhaled maintenance therapy
• Competitive intensity: other inhaled antipseudomonal antibiotics and CF airway infection maintenance alternatives

How is revenue typically distributed within the tobramycin family?

For investment and pipeline decisions, the practical split is:

• Inhaled CF maintenance: primary volume and payer coverage engine
• Other routes (e.g., ophthalmic/topical): smaller, indication-separated markets with different procurement patterns

Because tobramycin sulfate itself is a generic active, the market is not a single SKU: revenue maps to legacy brand/nebulizer formats and to generic substitution rates under local tendering.

Where pricing pressure comes from

In mature antibiotic maintenance franchises, pricing pressure is structurally driven by:

• Generic entry (device-linked substitution varies by market)
• Formulary moves within CF care pathways
• Competitive switching among inhaled alternatives, often by dosing convenience and tolerability

Competitive framework (how to benchmark positioning)

Benchmark tobramycin sulfate against other inhaled antipseudomonal maintenance strategies that compete on:

• Dosing schedule (cycle vs continuous)
• Device convenience and adherence (nebuli time and usability)
• Lung function endpoints and exacerbation reduction narratives
• Safety monitoring burden (aminoglycoside class effects)

What market projection should be used for tobramycin sulfate?

A numeric projection requires:

• Confirmed current revenue baselines by geography and route
• Country-level generic penetration rates for each tobramycin formulation
• Competitive adoption curves for inhaled CF maintenance alternatives
• Unit demand assumptions (treated CF population, dosing cycles)

This response cannot provide a complete projection table with hard numbers because those inputs are not present in the prompt, and the constraint requires hard data only.

What are the highest-impact drivers for future performance?

Even without numeric forecasts, the drivers that determine whether the franchise grows, stabilizes, or declines are consistent:

Demand-side

• CF treated population size and diagnosis rates
• Persistence/adherence to chronic inhaled regimens
• Switching behavior within CF maintenance algorithms

Supply-side

• Generic substitution speed by country and tender structures
• Device platform standardization (nebuli system requirements can slow substitution)
• Manufacturing scale stability and supply continuity

Clinical and regulatory-side

• Evidence generation strategy: equivalence/non-inferiority versus inhaled comparators
• Label expansions or formulation updates (if any) that change payer coverage

Operational implications for R&D and investment decisions

If the goal is to evaluate tobramycin sulfate competitively, the actionable lens is formulation and delivery:

• A new formulation or device must clear endpoints that payers and guidelines recognize
• Clinical trial costs can be reduced if the design targets regulators’ established acceptance for inhaled aminoglycosides (comparative PK/PD and clinically grounded non-inferiority)
• Commercial success depends on contracting and substitution rules more than on active ingredient differentiation

---

Key Takeaways

• Tobramycin sulfate’s commercial value concentrates in inhaled maintenance therapy for CF chronic P. aeruginosa, where legacy dosing structures and comparator benchmarks strongly shape trial design.
• Market dynamics are dominated by formulation/device competition and generic substitution, which create durable pricing pressure.
• A numeric clinical trials update and market projection require a verified trial registry extract and audited market baseline inputs, which are not included in this prompt.

---

FAQs

1) Is tobramycin sulfate primarily a cystic fibrosis drug commercially?
In practice, the largest and most consistent chronic use is inhaled tobramycin for CF chronic P. aeruginosa infection.

2) Why do trials for tobramycin often focus on formulation rather than new biology?
The active ingredient and its clinical efficacy and safety framework are established; newer studies often target equivalent delivery, tolerability, and adherence improvements.

3) What most affects tobramycin revenue: demand growth or pricing?
Pricing and substitution speed usually dominate in mature antibiotic franchises, with demand changes smaller and slower moving.

4) How do competitors influence tobramycin performance?
Competitors in inhaled CF maintenance shift utilization based on dosing convenience, tolerability, and clinical endpoint positioning.

5) Does “tobramycin sulfate” equal one product in the market?
No. The market depends on route and formulation, and revenue is tied to specific inhaled product platforms and their substitution dynamics.

---

References

[1] ClinicalTrials.gov. Tobramycin sulfate search results. https://clinicaltrials.gov/
[2] European Union Clinical Trials Register. Search for tobramycin sulfate. https://www.clinicaltrialsregister.eu/
[3] U.S. FDA. Drug Safety Communications and approved labeling resources for tobramycin products (route-specific). https://www.fda.gov/